Sign In
Buy AMN
$30.31
+0.0600 (+0.198%)
At Close: Jun 03, 2026
AMN Healthcare (AMN) is on the Move, Here's Why the Trend Could be Sustainable
12:50pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
AMN Healthcare (AMN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through
AMN Healthcare (AMN) is on the Move, Here's Why the Trend Could be Sustainable
10:32am, Wednesday, 26'th Oct 2022
AMN Healthcare (AMN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
09:45pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
AMN Healthcare Services (AMN) closed at $120.04 in the latest trading session, marking a +1.59% move from the prior day.
Philips' (PHG) Q3 Earnings Down on Supply Chain Constraints
03:46pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Koninklijke Philips' (PHG) Q3 top and bottom-line results reflect the negative impact of supply chain constraints, COVID lockdowns in China and the Russia-Ukraine war.
Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?
01:40pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?
11:19am, Tuesday, 25'th Oct 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Abiomed's (ABMD) Latest Impella Offering Approved by the FDA
04:36pm, Friday, 21'st Oct 2022 Zacks Investment Research
Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.
Veeva Systems' (VEEV) New Launch to Streamline Clinical Data
04:17pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.
Buy These 4 Low-Beta Stocks to Combat Market Volatility
12:40pm, Thursday, 20'th Oct 2022 Zacks Investment Research
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Scorpio Tankers Inc. (STNG), AMN Healthcare (AMN), Ardmore (ASC) and Lancaster (LANC) are poised to gain.
Buy These 4 Low-Beta Stocks to Combat Market Volatility
09:47am, Thursday, 20'th Oct 2022
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Scorpio Tankers Inc. (STNG), AMN Healthcare (AMN), Ardmore (ASC) and Lancaster (LANC) are poised to gain.
Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover
04:16pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.
Veeva Systems' (VEEV) New Launch to Enhance Digital Trials
01:27pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.
BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence
04:35pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
04:10pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
04:00pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
